Delamanid: A new armor in combating drug-resistant tuberculosis

Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from Europea...

Descripción completa

Detalles Bibliográficos
Autores principales: Xavier, Alphienes Stanley, Lakshmanan, Mageshwaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Molecules of the Millennium
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156838/
https://www.ncbi.nlm.nih.gov/pubmed/25210407
http://dx.doi.org/10.4103/0976-500X.136121
_version_ 1782333788861235200
author Xavier, Alphienes Stanley
Lakshmanan, Mageshwaran
author_facet Xavier, Alphienes Stanley
Lakshmanan, Mageshwaran
author_sort Xavier, Alphienes Stanley
collection PubMed
description Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability.
format Online
Article
Text
id pubmed-4156838
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-41568382014-09-10 Delamanid: A new armor in combating drug-resistant tuberculosis Xavier, Alphienes Stanley Lakshmanan, Mageshwaran J Pharmacol Pharmacother Molecules of the Millennium Intense search has been made in the discovery of newer anti-TB drugs to tackle the issues such as drug resistance, HIV co-infection and risk of drug-drug interactions in the management of TB. Delamanid, a newer mycobacterial cell wall synthesis inhibitor, received a conditional approval from European medicines agency (EMA) for the treatment of MDR-TB. Preclinical and clinical studies have shown that delamanid has high potency, least risk for drug-drug interactions and better tolerability. Medknow Publications & Media Pvt Ltd 2014 /pmc/articles/PMC4156838/ /pubmed/25210407 http://dx.doi.org/10.4103/0976-500X.136121 Text en Copyright: © Journal of Pharmacology and Pharmacotherapeutics http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Molecules of the Millennium
Xavier, Alphienes Stanley
Lakshmanan, Mageshwaran
Delamanid: A new armor in combating drug-resistant tuberculosis
title Delamanid: A new armor in combating drug-resistant tuberculosis
title_full Delamanid: A new armor in combating drug-resistant tuberculosis
title_fullStr Delamanid: A new armor in combating drug-resistant tuberculosis
title_full_unstemmed Delamanid: A new armor in combating drug-resistant tuberculosis
title_short Delamanid: A new armor in combating drug-resistant tuberculosis
title_sort delamanid: a new armor in combating drug-resistant tuberculosis
topic Molecules of the Millennium
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156838/
https://www.ncbi.nlm.nih.gov/pubmed/25210407
http://dx.doi.org/10.4103/0976-500X.136121
work_keys_str_mv AT xavieralphienesstanley delamanidanewarmorincombatingdrugresistanttuberculosis
AT lakshmananmageshwaran delamanidanewarmorincombatingdrugresistanttuberculosis

Ejemplares similares